Zacks Research Analysts Increase Earnings Estimates for HALO

Key Points

• Zacks Research analysts have raised their earnings estimates for Halozyme Therapeutics, projecting Q1 2026 earnings at $1.00 per share, an increase from the previous estimate of $0.94.
• Halozyme Therapeutics recently reported Q2 earnings of $1.54 per share, surpassing the consensus estimate of $1.23, with a significant revenue increase of 40.8% year-over-year.
• The stock has an average rating of "Hold" from analysts, with a consensus target price of $70.44 and recent adjustments to price targets from several investment firms.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Investment analysts at Zacks Research boosted their Q1 2026 earnings estimates for shares of Halozyme Therapeutics in a research report issued to clients and investors on Tuesday, October 7th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings of $1.00 per share for the quarter, up from their previous forecast of $0.94. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q2 2026 earnings at $1.28 EPS, Q3 2026 earnings at $1.49 EPS, FY2026 earnings at $5.75 EPS and Q2 2027 earnings at $1.48 EPS.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $325.72 million during the quarter, compared to analysts' expectations of $282.66 million. During the same period last year, the business earned $0.91 EPS. The business's quarterly revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS.

Other equities research analysts have also recently issued reports about the company. Morgan Stanley lifted their target price on Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a research note on Monday, August 18th. Wall Street Zen cut Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. Benchmark raised their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a "buy" rating in a research report on Wednesday, September 24th. The Goldman Sachs Group initiated coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price objective on the stock. Finally, HC Wainwright lifted their target price on Halozyme Therapeutics from $85.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, October 2nd. Five research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $70.44.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $66.02 on Wednesday. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. Halozyme Therapeutics has a 52-week low of $42.01 and a 52-week high of $79.50. The stock's 50 day moving average price is $70.77 and its two-hundred day moving average price is $61.97. The stock has a market capitalization of $7.72 billion, a price-to-earnings ratio of 15.11, a PEG ratio of 0.36 and a beta of 1.16.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Isthmus Partners LLC grew its stake in shares of Halozyme Therapeutics by 2.5% in the first quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company's stock worth $439,000 after purchasing an additional 169 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Halozyme Therapeutics by 6.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company's stock valued at $140,000 after acquiring an additional 174 shares during the period. OneDigital Investment Advisors LLC boosted its stake in Halozyme Therapeutics by 1.7% during the first quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company's stock worth $649,000 after acquiring an additional 175 shares in the last quarter. Park Place Capital Corp lifted its stake in shares of Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock worth $69,000 after buying an additional 182 shares in the last quarter. Finally, Xponance Inc. increased its holdings in Halozyme Therapeutics by 1.1% during the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company's stock valued at $1,190,000 after buying an additional 198 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 2,227 shares of the company's stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $77.95, for a total value of $173,594.65. Following the completion of the sale, the chief financial officer directly owned 22,079 shares in the company, valued at $1,721,058.05. This represents a 9.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Helen Torley sold 20,000 shares of the company's stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $69.03, for a total transaction of $1,380,600.00. Following the sale, the chief executive officer owned 733,719 shares of the company's stock, valued at $50,648,622.57. This trade represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 108,227 shares of company stock worth $7,779,595 over the last quarter. 2.90% of the stock is currently owned by insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.